The Results of the IBIS II Trial

Article

Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

Clinical Pearls:

  • IBIS II is a prevention study in over 3,000 women who were randomized to anastrozole vs placebo
  • Anastrozole proved to be 50% effective in presenting breast cancer, primarily ER+ breast cancer, compared to the placebo
  • There was only a 10% difference in the grades of musculoskeletal arthralgias when comparing anastrozole to the placebo
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content